Harbor Advisors’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Harbor Advisors’s Portfolio IBER.U Stock Details IBER.U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,000	Closed	-$98K	–	176
2022 Q2	$98K	Hold	10,000	–	–	0.02%	159
2022 Q1	$99K	Hold	10,000	–	–	0.02%	169
2021 Q4	$100K	Hold	10,000	–	–	0.02%	174
2021 Q3	$100K	Hold	10,000	–	–	0.02%	166
2021 Q2	$101K	Hold	10,000	–	–	0.02%	169
2021 Q1	$99K	Buy	+10,000	New	+$100K	0.02%	188

Other funds holding IBER.U

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.43B AUM 16.47% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Harbor Advisors's IBER.U Position: Q3 2022 in Review

Harbor Advisors sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q3 2022, closing a stake of 10,000 shares — an estimated $98K sold.

Harbor Advisors first reported a position in IBER.U in Q1 2021 and held it in 6 quarters. The position peaked at $101K in Q2 2021. 13 funds tracked by Wall St. Rank hold IBER.U as of Q3 2022.

Harbor Advisors reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q3 2022 after selling out during the quarter.
Harbor Advisors sold 10,000 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q3 2022, an estimated $98K.
Harbor Advisors first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 6 quarters.
Harbor Advisors's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $101K in Q2 2021.
13 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q3 2022.

Based on Harbor Advisors's 13F filing for Q3 2022, filed 7 Nov 2022.